Vanguard Group Inc Chinook Therapeutics, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $1.87 Million - $3.87 Million	100,330 Added 3.52%	2,948,165 $113 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $1.19 Million - $1.48 Million	55,261 Added 1.98%	2,847,835 $65.9 Million
Q4 2022 Feb 10, 2023	BUY	$18.63 - $27.35 $7.32 Million - $10.7 Million	392,808 Added 16.37%	2,792,574 $73.2 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $651,196 - $869,130	37,190 Added 1.57%	2,399,766 $47.2 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $6.71 Million - $10 Million	533,204 Added 29.15%	2,362,576 $41.3 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $515,153 - $715,300	42,858 Added 2.4%	1,829,372 $29.9 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $3.76 Million - $5.92 Million	351,818 Added 24.52%	1,786,514 $29.1 Million
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $506,989 - $655,117	44,086 Added 3.17%	1,434,696 $18.3 Million
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $18.9 Million - $26.4 Million	1,390,610 New	1,390,610 $19.6 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.